Coagulation Factor Xa: The Prothrombinase Complex as an Emerging Therapeutic Target for Small Molecule Inhibitors

1998 ◽  
Vol 14 (1) ◽  
pp. 15-25 ◽  
Author(s):  
Robert M. Scarborough
2004 ◽  
Vol 1 (1) ◽  
pp. 129-152 ◽  
Author(s):  
Henry W. Pauls ◽  
William R. Ewing ◽  
Yong M. Choi-Sledeski

Blood ◽  
2021 ◽  
Author(s):  
Eliza A Ruben ◽  
Michael J Rau ◽  
James Fitzpatrick ◽  
Enrico Di Cera

Coagulation factor V is the precursor of factor Va that, together with factor Xa, Ca2+ and phospholipids, defines the prothrombinase complex and activates prothrombin in the penultimate step of the coagulation cascade. Here we present cryo-EM structures of human factors V and Va at atomic (3.3 Å) and near-atomic (4.4 Å) resolution, respectively. The structure of fV reveals the entire A1-A2-B-A3-C1-C2 assembly but with a surprisingly disordered B domain. The C1 and C2 domains provide a platform for interaction with phospholipid membranes and support the A1 and A3 domains, with the A2 domain sitting on top of them. The B domain is highly dynamic and visible only for short segments connecting to the A2 and A3 domains. The A2 domain reveals all sites of proteolytic processing by thrombin and activated protein C, a partially buried epitope for binding factor Xa and fully exposed epitopes for binding activated protein C and prothrombin. Removal of the B domain and activation to fVa exposes the sites of cleavage by activated protein C at R306 and R506 and produces increased disorder in the A1-A2-A3-C1-C2 assembly, especially in the C-terminal acidic portion of the A2 domain responsible for prothrombin binding. Ordering of this region and full exposure of the factor Xa epitope emerge as a necessary step for the assembly of the prothrombin-prothrombinase complex. These structures offer molecular context for the function of factors V and Va and pioneer the analysis of coagulation factors by cryo-EM.


Blood ◽  
2014 ◽  
Vol 124 (25) ◽  
pp. 3730-3737 ◽  
Author(s):  
Marcelo J. Murai ◽  
Jonathan Pollock ◽  
Shihan He ◽  
Hongzhi Miao ◽  
Trupta Purohit ◽  
...  

Key Points Inhibiting LEDGF interaction with a novel fragment of MLL represents an attractive approach to develop new drugs for MLL leukemias. Structural studies reveal a new pocket on the LEDGF IBD suitable for targeting by small-molecule inhibitors.


ChemMedChem ◽  
2011 ◽  
Vol 6 (6) ◽  
pp. 1049-1066 ◽  
Author(s):  
Robert Abel ◽  
Noeris K. Salam ◽  
John Shelley ◽  
Ramy Farid ◽  
Richard A. Friesner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document